132eP Prognostic uncertainty in refractory mCRC: Evaluating outcomes with TAS-102 plus bevacizumab beyond traditional classification in a real-world setting
Titel:
132eP Prognostic uncertainty in refractory mCRC: Evaluating outcomes with TAS-102 plus bevacizumab beyond traditional classification in a real-world setting
Auteur:
Frazão, P. Monteiro, C.A.L.D.B. Martins, T.S.C. Gramaça, J. Verdasca, F.R. Margarido, I. Ferreira, A. Luís, J.G. Alves Neves, M.T. de Almeida, S.B. Duarte, T.M. Pina-Cabral, T. Lagarto, M. Ferraz de Liz, F. Fonseca, V.L. Martins, A.